BIO-TECHNE Corp Finite-Lived Intangible Assets, Gross
BIO-TECHNE Corp (TECH) had Finite-Lived Intangible Assets, Gross of $895.19 million as of 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsGross · last filed 2026-08-24
- 2026-06-30: Finite-Lived Intangible Assets, Gross $895.19M.
- 2026-03-31: Finite-Lived Intangible Assets, Gross $895.88M.
- 2025-12-31: Finite-Lived Intangible Assets, Gross $897.15M.
- 2025-09-30: Finite-Lived Intangible Assets, Gross $896.56M.
| Period end | Finite-Lived Intangible Assets, Gross |
|---|---|
| 2026-06-30 | $895.19M 10-K · filed 2026-08-24 |
| 2026-03-31 | $895.88M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $897.15M 10-Q · filed 2026-02-04 |
| 2025-09-30 | $896.56M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $997.65M 10-K · filed 2026-08-24 |
| 2025-03-31 | $1.05B 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.05B 10-Q · filed 2025-02-06 |
| 2024-09-30 | $1.06B 10-Q · filed 2024-11-05 |
| 2024-06-30 | $1.05B 10-K · filed 2025-08-22 |
| 2024-03-31 | $1.03B 10-Q · filed 2024-05-06 |
| 2023-12-31 | $1.04B 10-Q · filed 2024-02-07 |
| 2023-09-30 | $1.06B 10-Q · filed 2023-11-07 |
| 2023-06-30 | $992.51M 10-K · filed 2024-08-22 |
| 2023-03-31 | $1.00B 10-Q · filed 2023-05-08 |
| 2022-12-31 | $996.54M 10-Q · filed 2023-02-07 |
| 2022-09-30 | $991.63M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $924.00M 10-K · filed 2023-08-23 |
| 2022-03-31 | $929.79M 10-Q · filed 2022-05-09 |
| 2021-06-30 | $941.53M 10-K · filed 2022-08-24 |
| 2020-06-30 | $795.59M 10-K · filed 2021-08-25 |
| 2020-03-31 | $792.82M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $800.71M 10-Q · filed 2020-02-06 |
| 2019-09-30 | $797.01M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $799.43M 10-K · filed 2020-08-26 |
| 2019-03-31 | $784.36M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $798.06M 10-Q · filed 2019-02-07 |
| 2018-06-30 | $608.54M 10-K/A · filed 2019-11-06 |
| 2018-03-31 | $600.42M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $582.62M 10-Q · filed 2018-02-08 |
| 2017-09-30 | $583.84M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $572.19M 10-K · filed 2018-08-27 |
| 2017-03-31 | $590.78M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $589.65M 10-Q · filed 2017-02-09 |
| 2016-09-30 | $589.41M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $378.72M 10-K · filed 2017-09-07 |
| 2016-03-31 | $387.01M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $379.77M 10-Q · filed 2016-02-09 |
| 2015-09-30 | $382.89M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $343.55M 10-K · filed 2016-08-29 |
| 2015-03-31 | $340.75M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $350.75M 10-Q · filed 2015-02-09 |
| 2014-09-30 | $338.68M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $134.79M 10-K · filed 2015-08-31 |
| 2014-03-31 | $118.97M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $118.74M 10-Q · filed 2014-02-04 |
| 2013-09-30 | $117.93M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $55.33M 10-K · filed 2014-08-29 |
| 2013-03-31 | $55.31M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $57.57M 10-Q · filed 2013-02-11 |
| 2012-09-30 | $57.38M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $56.39M 10-K · filed 2013-08-29 |
| 2012-03-31 | $57.06M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $56.04M 10-Q · filed 2012-02-07 |
| 2011-09-30 | $56.14M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $57.15M 10-K · filed 2012-08-29 |
| 2010-06-30 | $5.45M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |